Abstracts tagged "Administrative Data"

Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 1271 • ACR Convergence 2024
Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset
Jordan Roberts¹, Anna Faino², Min-Lee Chang³, Jonathan Cogen⁴, Matt Hall⁵ and Esi Morgan¹, and for the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ⁴Seattle Children’s Hospital, Seattle, WA, ⁵Children’s Hospital Association, Lenexa, KS
Background/Purpose: Currently, no comprehensive national multipayer dataset with inpatient and outpatient data exists for childhood rheumatologic diseases, limiting the ability to study outcomes longitudinally and…
Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Sharan Rai¹, Gregory Challener¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
Abstract Number: 1315 • ACR Convergence 2024
From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018
Shreena Kamlesh Gandhi¹, Shivani Patel², Saransh Narang³, Aayushi Rajani³ and Kaleb Michaud⁴, ¹KU School of Medicine, Wichita, Wichita, KS, ²Washington University in St. Louis, St. Louis, MO, ³Medical College, Baroda, Baroda, India, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR Convergence meeting attracts rheumatology researchers worldwide to present their peer- reviewed abstracts for a global audience either as a poster or oral…
Abstract Number: 2491 • ACR Convergence 2024
Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, Danuta Kielar⁵, Juliana Meyers⁶, Elizabeth Esterberg⁶, Tram Nham⁶ and Stephanie Y. Chen⁷, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, ⁶RTI Health Solutions, Research Triangle Park, NC, ⁷BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis disorder characterized by asthma, eosinophilia and the presence of eosinophilic inflammation. Patients with EGPA are…
Abstract Number: 0199 • ACR Convergence 2024
Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Mangala Rajan², Orysya Soroka², Karen Onel³, Monika Safford² and Iris Navarro Millan⁴, ¹Weill Cornell Medicine/ Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: 50-80% of children with childhood-onset systemic lupus erythematosus (cSLE) develop lupus nephritis (LN). Children from historically marginalized communities are disproportionately affected by cSLE and…
Abstract Number: 1606 • ACR Convergence 2024
Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, James M. Eudicone⁵, Amanda M. Moore⁶, Melissa Wilson⁷, Kinwei A. Chan⁶, Thomas Peer⁸ and Stephanie Y. Chen⁹, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁶TriNetX, Cambridge, MA, ⁷TriNetX, Durham, NC, ⁸TriNetX, Farmington, NY, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
Abstract Number: 2587 • ACR Convergence 2024
A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications
Tanishka Agrawal¹, Sumanth Raman², J. Arun³ and HUMEIRA BADSHA⁴, ¹Dubai International Academy, Dubai, Dubai, United Arab Emirates, ²Algorithm Health, Dubai, Dubai, United Arab Emirates, ³Algorithm Health, Dubai, United Arab Emirates, ⁴HBMC, Dubai, United Arab Emirates
Background/Purpose: Patients with chronic autoimmune conditions often need expensive treatments which require prior authorizations by insurance companies. However, significant delays in these processes leave patients…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 1716 • ACR Convergence 2024
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Kasra Moolooghy¹, Hui Xie², Yufei Zheng³, J. Antonio Avina-Zubieta¹ and Diane Lacaille¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…
Abstract Number: 2621 • ACR Convergence 2024
Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records
David Cheng¹, Vidul Panickan², Andrew Cagan³, Gregory McDermott⁴, Mary Jeffway³, Ying Qi⁵, Feng Liu³, Michael Weinblatt⁶, Nancy Shadick⁵, Tianxi Cai⁷ and Katherine Liao³, ¹Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Brookline, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…
Abstract Number: 0490 • ACR Convergence 2024
Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Hip or pelvis fractures (HOP) are common osteoporotic fractures (OP) with significant risks of medical complications, placement into care, reduced quality of life and…
Abstract Number: 1717 • ACR Convergence 2024
Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Md Rashedul Hoque¹, Diane Lacaille², J. Antonio Avina-Zubieta², Mary A. De Vera³, Yi Qian⁴, John Esdaile⁵ and Hui Xie⁶, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, Canada, ⁵Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and hospitalization costs among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods: We…
Abstract Number: 2622 • ACR Convergence 2024
Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring
Emily Smitherman¹, Justin Leach¹, Aimee Hersh², Melissa Mannion¹, Jinoos Yazdany³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³UCSF, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Poorly controlled childhood-onset lupus nephritis (cLN) can lead to end-stage kidney disease (ESKD), requiring kidney replacement therapies with substantial financial and quality of life…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].